Form 4: Intellia Therapeutics Director Frank Verwiel Sells 1,505 Shares Under 10b5-1 Plan
SEC Form 4 Filing
Frank Verwiel, a director at Intellia Therapeutics, sold 1,505 shares of common stock at $25 per share on June 17, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On June 17, 2024, Frank Verwiel, a director of Intellia Therapeutics, Inc. (NTLA), sold 1,505 shares of common stock.
- The sale was executed at a price of $25 per share.
- The transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on March 7, 2024.
- Following the transaction, Verwiel directly owns 17,948 shares of Intellia Therapeutics.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The use of a 10b5-1 plan suggests the sale was pre-planned and doesn't necessarily reflect a negative outlook on the company.
Industry Context
Sales by insiders are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the insider is selling shares in a pre-planned manner to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by a director could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date the reporting person adopted the 10b5-1 trading plan |
| 06/17/2024 | Date of the transaction (stock sale) |
| 06/20/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.